The invention concerns chemical compounds of formula I R.sup.1 --CON(R.sup.2)--CON(R.sup.3)--X.sup.1 --Q--X.sup.2 --GI and pharmaceutically acceptable metabolically labile esters or amides thereof, and pharmaceutically acceptable salts thereof, in which R.sup.1, R.sup.2, R.sup.3, X.sup.1, Q, X.sup.2 and G have the meanings given in the specification. The invention concerns processes for the preparation of the chemical compounds of formula I, pharmaceutical compositions containing them and their use as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa.
本发明涉及
化学式I的化合物,其中R.sup.1 -CON(R.sup.2)-CON(R.sup.3)-X.sup.1-Q-X.sup.2-GI以及其在代谢易降解的酯或酰胺和药学上可接受的盐中。其中,R.sup.1、R.sup.2、R.sup.3、X.sup.1、Q、X.sup.2和G的含义如规范中所述。本发明涉及制备
化学式I的化合物的方法、含有它们的制药组合物以及它们作为
纤维蛋白原与糖蛋白IIb/IIIa结合
抑制剂的用途。